BAY 1000394 is primarily investigated for its potential in cancer therapy. It functions as an Aurora kinase inhibitor, targeting Aurora kinases A and B involved in cell cycle regulation and mitosis. By inhibiting these kinases, it can disrupt the proliferation and survival of cancer cells, making it a promising candidate for treating various types of cancers, particularly those driven by abnormal mitotic progression. Research is ongoing to evaluate its efficacy and safety in preclinical and clinical settings, with a focus on its role in combination therapies or as a standalone treatment for resistant cancers.